

Unipharm Limited

IFS Court, TwentyEight, Cybercity, Ebene, Mauritius
Tel: (230) 467 3000 Fax: (230) 467 4000

Ref: AM/SN/FA

(Please quote our reference in your reply)

6 September 2012

By courier

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Mumbai – 400 001
India

The National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai – 400 001
India

Scrip Code: 524558

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sir

Sale of shares by UNIPHARM LIMITED

Submission of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

We wish to inform you that the Company has sold 220,000 equity shares of Neuland Laboratories Limited to Neuland Health Sciences Pvt. Ltd. (Formerly Sucheth and Saharsh Holdings Pvt. Ltd.).

The required proforma for disclosure is enclosed. We request you to kindly take the above information on record.

Thanking you

Yours faithfully



Kapildeo Joory

Director and Authorized Signatory

encs

cc: Neuland Laboratories Limited, Hyderabad

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Neuland Laboratories Limited		
2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Neuland Health Sciences Pvt. Ltd. (Formerly Sucheth and Saharsh holdings Pvt. Ltd.)		
3. Whether the acquirer belongs to Promoter/Promoter group	Yes		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE, NSE		
5. Details of the acquisition—/ disposal/holding of shares/voting rights/holding of the Acquirer and PAC	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC(*)
<u>Before the acquisition/disposal under consideration, holding of:</u>			
a) Shares carrying voting rights	820,000	10.73%	--
b) Voting rights (VR) otherwise than by shares	--	--	--
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	--	--	--
Total (a+b+c)	820,000	10.73%	--
<u>Details of acquisition/sale</u>			
a) Shares carrying voting rights acquired/sold	220,000	2.88%	--
b) VRs acquired /sold otherwise than by shares	--	--	--
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	--	--	--

Total (a+b+c)	220,000	2.88%	---
<u>After the acquisition/sale, holding of:</u>			
a) Shares carrying voting rights	600,000	7.85%	--
b) VRs otherwise than by shares	--	--	--
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.	--	--	--
Total (a+b+c)	600,000	7.85%	---
6. Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Off-market		
7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	3 September 2012		
8. Equity share capital / total voting capital of the TC before the said acquisition / sale	7,644,978 equity shares @ INR10 each		
9. Equity share capital/ total voting capital of the TC after the said acquisition / sale	7,644,978 equity shares @ INR10 each		
10. Total diluted share/voting capital of the TC after the said acquisition/sale.	N.A.		

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

UNIPHARM LIMITED



Kapildeo Joory

Director and Authorised Signatory

Place: Mauritius

Date: 6 September 2012